scholarly journals Synchronous Occurrence of Guillain-Barre Syndrome and Transverse Myelitis of Unknown Etiology in an Adolescent

Cureus ◽  
2020 ◽  
Author(s):  
Ankit Agarwal ◽  
Adriana Fernandez Bowman
Keyword(s):  
Transverse Myelitis ◽  
Guillain Barre Syndrome ◽  
Unknown Etiology ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Guillain-Barré Syndrome associated with the coronavirus disease 2019 (COVID-19)

2020 ◽  
pp. 10.1212/CPJ.0000000000000879 ◽  
Author(s):  
Seyed Amir Ebrahimzadeh ◽  
Abdoreza Ghoreishi ◽  
Nasrin Rahimian
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Respiratory Symptoms ◽  
Guillain Barre Syndrome ◽  
Unknown Etiology ◽  
Neurologic Complications ◽  
Wuhan City ◽  
First Case ◽  
Guillain Barré Syndrome ◽  
Novel Coronavirus ◽  
Guillain Barré

In December 2019, the first case of pneumonia with unknown etiology was reported in Wuhan city, China. The identified pathogen was a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).1 Since then, the virus has spread rapidly worldwide. Although Coronavirus disease 2019 (COVID-19) typically presents with upper or lower respiratory symptoms, there have been rare reports of significant neurologic complications.2,3 Recently, a few reports presented cases of Guillain-Barré syndrome (GBS) after COVID-19.4,5 In this report, we describe 2 cases of GBS that occurred following COVID-19.

scholarly journals Transverse Myelitis and Guillain-Barré Syndrome Overlap Secondary to Bartonella henselae: Case Report

2019 ◽  
Vol 120 (4) ◽  
pp. 131-137
Author(s):  
Jamir Pitton Rissardo ◽  
Ana Letícia Fornari Caprara
Keyword(s):  
Bartonella Henselae ◽  
Case Reports ◽  
Plantar Flexion ◽  
Transverse Myelitis ◽  
Guillain Barre Syndrome ◽  
Simultaneous Occurrence ◽  
Present Moment ◽  
Serological Tests ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

The GBS/ATM overlap is characterized by the simultaneous occurrence of Guillain-Barré syndrome (GBS) and acute transverse myelitis (ATM), which are two neurological autoimmune disorders. In this context, cat scratch disease (CSD) was rarely reported combined with this overlap. An adult female presenting fever, back pain, inferior limb weakness, and anuria was admitted to our hospital. On the physical exam, a distended bladder and bilateral lymphadenopathy were observed. The neurological assessment revealed muscle weakness, plantar flexion, and hyporeflexia in right with absence in left. Also, she reported hyperalgesia in inferior limbs. Her blood pressure was fluctuating being in the majority of the time hypertensive. A spinal cord MRI (magnetic resonance imaging) was suggestive of transverse myelitis. Methylprednisolone was started. The cerebrospinal fluid showed 37.0 cells/mm3 of white blood cell count, 49 mg/dl of glucose, and 50.7 mg/dl of protein. Ceftriaxone and vancomycin were started. On further questioning, the subject stated that her finger was bitten by a cat about two weeks before the beginning of the symptoms. Serological tests were positive for Bartonella henselae. Doxycycline and rifampin were started. After one-month, her symptoms improve but she continued with a radicular pain and weakness. An EMG (electroneuromyography) was suggestive of demyelination. IVIG (intravenous immunoglobulin) was started. After IVIG 4-day, the patient had recovery of her strength. To the authors’ knowledge, there are two case reports of pediatric individuals linking CSD and GBS/ATM. Still, this association in an adult patient has not been reported until the present moment.

scholarly journals Guillain–Barré syndrome, transverse myelitis and infectious diseases

2018 ◽  
Vol 15 (6) ◽  
pp. 547-562 ◽  
Author(s):  
Yhojan Rodríguez ◽  
Manuel Rojas ◽  
Yovana Pacheco ◽  
Yeny Acosta-Ampudia ◽  
Carolina Ramírez-Santana ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Transverse Myelitis ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Association between COVID-19 vaccination, infection, and risk of Guillain-Barre syndrome, Bell's palsy, encephalomyelitis and transverse myelitis: a population-based cohort and self-controlled case series analysis

2021 ◽  
Author(s):  
Xintong Li ◽  
Eugenia Martinez-Hernandez ◽  
Elena Roel Herranz ◽  
Antonella Delmestri ◽  
Talita Duarte-Salles ◽  
...  
Keyword(s):  
General Population ◽  
Statistical Power ◽  
Case Series ◽  
Transverse Myelitis ◽  
Bell’S Palsy ◽  
Population Based ◽  
Guillain Barre Syndrome ◽  
Bell's Palsy ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

OBJECTIVE We aimed to study the association between COVID-19 vaccines, SARS-CoV-2 infection, and the risk of immune-mediated neurological events. METHODS Design Population-based historical rate comparison study and self-controlled case series (SCCS) analysis. Setting Primary care records from the United Kingdom. Participants Individuals who received the first dose of ChAdOx1 or BNT162b2 between 8 December 2020 and 6 March 2021. A cohort with a first positive RT-PCR test for SARS-CoV-2 between 1 September 2020 and 28 February 2021 was used for comparison. Main outcome measures Outcomes included Guillain-Barre syndrome (GBS), Bell's palsy, encephalomyelitis, and transverse myelitis. Incidence rates were estimated in the 28 days post first-dose vaccine, 90 days post-COVID-19, and between 2017 to 2019 for the general population cohort for background rates. Indirectly standardised incidence ratios (SIRs) were estimated. Adjusted incidence rate ratios (IRR) were estimated from the SCCS when sufficient statistical power was reached. Results We included 1,868,767 ChAdOx1 and 1,661,139 BNT162b2 vaccinees; 299,311 people infected with COVID-19; and 2,290,537 from the general population. SIRs for GBS were 1.91 [95% CI: 0.86 to 4.26] after ChAdOx1, 1.29 [0.49 to 3.45] after BNT162b2, and 5.20 [1.95 to 13.85] after COVID-19. In the same cohorts, SIRs for Bell's palsy were 1.34 [1.05 to 1.72], 1.15 [0.88 to 1.50], and 1.23 [0.80 to 1.89], and for encephalomyelitis 1.62 [0.61 to 4.31], 0.86 [0.22 to 3.46], and 11.05 [5.27 to 23.17], respectively. Transverse myelitis was too rare to analyse (n<5 in all cohorts). SCCS analysis was only conducted for Bell's palsy due to limited statistical power. We found no association between either vaccine and Bell's palsy, with an IRR of 1.10 [0.81 to 1.46] and 1.15 [0.87 to 1.49] for BNT162b2 and ChAdOx1, respectively. Conclusions We found no consistent association between either vaccine and any of the studied neuro-immune adverse events studied. Conversely, we found a 5-fold increase in risk of GBS and an 11-fold of encephalomyelitis following COVID-19.

Sign in / Sign up

Export Citation Format

Share Document